Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-alcoholic Fatty Liver Disease: early-phase trial registry
19 of 58 indexed Non-alcoholic Fatty Liver Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #244 of 28,707 conditions by registered trial count.
58 US clinical trials · 19 currently recruiting · #244 of 28,707 conditions by registered trial count
Non-alcoholic Fatty Liver Disease: 58 US clinical trials tracked, 19 recruiting.
Non-alcoholic Fatty Liver Disease is the subject of 58 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 3 of these trials.
Enrollment posture brief
Registry condition non-alcoholic-fatty-liver-disease
OPEN 19 | RECR 33% | LATE 7 | EARLY 22 | RANK #244 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Diabetes Mellitus, Type 1 (33% recruiting · 119 trials)
Non-alcoholic Fatty Liver Disease lists 19 open slots (33% of 58 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-alcoholic Fatty Liver Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-alcoholic Fatty Liver Disease is recruiting below its size-band peers.
19 of 58 indexed trials (32.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-alcoholic Fatty Liver Disease trials is spread across many organizations.
Pfizer accounts for 3 of 58 trials (5.2%). 46 distinct sponsors appear on at least one study for this condition label.
-
Most Non-alcoholic Fatty Liver Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 58 trials that report a genuine target (sentinel values excluded). 39 of those (67.2%) plan for fewer than 100 participants.
-
Non-alcoholic Fatty Liver Disease research is mostly interventional.
48 interventional and 10 observational studies make up this index (82.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
58 total, page 1 of 2
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
GlaxoSmithKline
NCT07221188
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
AdventHealth Translational Research Institute
NCT04807868
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
GlaxoSmithKline
NCT07221227
The Olmsted NAFLD Epidemiology Study (TONES)
Mayo Clinic
NCT04365855
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
Brigham and Women's Hospital
NCT05728697
Fibrosis Lessens After Metabolic Surgery
Ali Aminian
NCT06374875
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT03884075
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
University of Alabama at Birmingham
NCT05268042
The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease
Vanderbilt University Medical Center
NCT06113003
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
Bettina Mittendorfer
NCT06571474
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
Yale University
NCT05067621
Quantifying Hepatic Mitochondrial Fluxes in Humans
The University of Texas Health Science Center at San Antonio
NCT05305287
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
Southern California Institute for Research and Education
NCT03073343
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
Marialena Mouzaki
NCT06133101
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Justin Ryder
NCT06355310
Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
Weill Medical College of Cornell University
NCT05332613
Human Models of Selective Insulin Resistance: Alpelisib, Part I
Columbia University
NCT06354088
Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
West Virginia University
NCT05507151
Intermittent Fasting for NAFLD in Adults
Massachusetts General Hospital
NCT04899102
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals
NCT04951219
Phase 2b Study of GSK4532990 in Adults With NASH
GlaxoSmithKline
NCT05583344
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
Rivus Pharmaceuticals
NCT05979779
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk
Washington University School of Medicine
NCT01104220
Prevention of NAFLD in Hispanic Children
Emory University
NCT05292352
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Merck Sharp & Dohme
NCT06465186
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
MediciNova
NCT05464784
Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease
AdventHealth Translational Research Institute
NCT05209100
Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease
M.D. Anderson Cancer Center
NCT04132440
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
Cirius Therapeutics
NCT02784444
Genetics of Fatty Liver Disease in Children
Yale University
NCT01966627
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
Methodist Health System
NCT05357352
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
Pfizer
NCT04321031
University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)
University of Florida
NCT00994682
Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children
Augusta University
NCT02383485
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
Merck Sharp & Dohme
NCT06482112
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
Zydus Therapeutics
NCT03061721
Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis
Pfizer
NCT04399538
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
Boehringer Ingelheim
NCT05970640
Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery
University of Massachusetts, Worcester
NCT01007955
Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production
University of Texas Southwestern Medical Center
NCT01262326
Phase I Trial of Silymarin for Chronic Liver Diseases
National Center for Complementary and Integrative Health (NCCIH)
NCT00389376
Healthy Liver - Healthy Brain
University of Texas at Austin
NCT05216796
6-week Safety and PD Study in Adults With NAFLD
Pfizer
NCT03256526
Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
University of California, San Diego
NCT01963845
Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation
HepQuant
NCT01579162
Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease
Amgen
NCT04857606
De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease
University of California, San Francisco
NCT00714129
Dietary Treatment Study of Pediatric NAFLD
University of California, San Diego
NCT02513121
Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates
University of Michigan
NCT00887393
Effect of Omega-3 PUFA Supplementation in NAFLD Patients
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00230113
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 17 |
| Phase 3 | 4 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-alcoholic Fatty Liver Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-alcoholic Fatty Liver Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-alcoholic Fatty Liver Disease page
58 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 19 Non-alcoholic Fatty Liver Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Non-alcoholic Fatty Liver Disease trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-alcoholic Fatty Liver Disease condition card totals 58 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.